Subscribe to Updates in Legal, Economic & Regulatory Affairs

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.




This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

Study Group: Medical Device Patent Experts: Lawyers (US)(?)

Council Members in this Study Group: 78

This study group may include professors, attorneys, former regulatory officers, and consultants knowledgeable on topics such as law and litigation issues, lobbying, policy and government, elections, antitrust, immigration, intellectual property, and legislation, among others.

Request a survey with this Study Group







Leading Experts in this Study Group

What is a GLG Leader?
Stephen Bent, Partner & Co-Chair, Life Sciences, Foley & Lardner LLPStephen Bent
Partner & Co-Chair, Life Sciences
Foley & Lardner LLP

Stephen A. Bent is Partner and co-leader of the Life Sciences Industry Team at Foley & Lardner in Washington, DC. He is also a member of the Biotechnology & Pharmaceutical Practice Group and the Health Care and Nanotechnology Industry Teams. Mr. Bent specializes on the legal issues associated with biotechnology...

Patrick Joseph Igoe, Life Sciences Patent Attorney, Independent IP Litigation ConsultantPatrick Joseph Igoe
Life Sciences Patent Attorney
Independent IP Litigation Consultant

Patrick Joseph Igoe is a consultant and registered patent attorney in New York. His focus is patent issues throughout Life Sciences - for example, diagnostic/therapeutic assays; medical devices/imaging technologies; Rx antibiotics, biologics, drugs, and vaccines; and OTC medicines. His expertise includes...

Thomas Saunders, Partner, Seyfarth Shaw LLPThomas Saunders
Partner
Seyfarth Shaw LLP

Thomas Saunders is a Partner at Seyfarth Shaw in Boston, Massachusetts, where he specializes in representing emerging medical technology, biotechnology/genetic engineering and pharmaceutical concerns, particularly as to patent prosecution, patent strategy, IP licensing matters and ANDA Paragraph IV...

Marc Scheineson, Partner & Chair, Food and Drug Practice, Alston & Bird LLPMarc Scheineson
Partner & Chair, Food and Drug Practice
Alston & Bird LLP

Marc Scheineson is a Partner with Alston & Bird where he heads the firm's Food and Drug Law Practice. He has practiced food and drug law, health care law and administrative law for over 20 years in national law firms and at the FDA. His practice focuses on determining the regulatory course of least...

Ted Frank, Resident Fellow & Director, Legal Center, American Enterprise Institute For Public Policy ResearchTed Frank
Resident Fellow & Director, Legal Center
American Enterprise Institute For Public Policy Research

Ted Frank is Resident Fellow and Director of the American Enterprise Institute Legal Center for the Public Interest in Washington, DC. Mr. Frank manages the Institute's research in and studies liability reform. His research areas include products liability (including pharmaceuticals and asbestos), class...

John Ryan, Partner, Crowell & Moring LLPJohn Ryan
Partner
Crowell & Moring LLP

John W. Ryan is a Partner at Crowell & Moring in Washington, DC, where he focuses on the chemical, biotechnology, medical device, and pharmaceutical industries. As the former Vice President and Chief Patent Counsel for IGEN International, he has managed various patent portfolios. Previously, Mr. Ryan...

GLG NewsSMAnalyses by this Study Group's Experts(?)

Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
Patent Win Protects Eisai's Aricept Against Teva's Potential Generic Product Launch Via Preliminary Injunction | 03-31-2008
Author: Patrick Joseph Igoe, Life Sciences Patent Attorney, Independent IP Litigation Consultant

* As noted in the Wall Street Journal article, Aricept® is a blockbuster drug for the treatment of Alzheimer's disease.  And, as noted in Judge Ackerman's ruling, Aricept sales are a huge source of Eisai's revenue - "sales of Aricept® in the United States constitute 70% of Eisai’s...

Amgen's EPO Patent Win At The Federal Circuit | 03-19-2008
Author: Patrick Joseph Igoe, Life Sciences Patent Attorney, Independent IP Litigation Consultant

(1) The US Court of Appeals for the Federal Circuit - in a complicated 22-page split Opinion earlier today Wed 19 Mar 2008 - provided Amgen another victory in its long patent battle(s) with Hoffmann-LaRoche. (2) Amgen's Aranesp® and EPOGEN® (each a prescription only product...

RIPENING INHIBITORS: ROSY FUTURE OR BRUISED FRUIT? | 12-21-2007
Author: Thomas Saunders, Partner, Seyfarth Shaw LLP

    Product shelf-life is a major economic concern for the agricultural industry.   The biological mechanism for regulating the ripening of fruits is mediated by ethylene.     Ethylene  management is addressed in three ways: 1) Ethylene...

FACTA's Billion Dollar Problem | 11-07-2007
Author: Ted Frank, Resident Fellow & Director, Legal Center, American Enterprise Institute For Public Policy Research

I discuss this issue (and other FACTA-related issues) at length in my latest Liability Outlook.

Neurontin® (Gabapentin) Patent Trials - Pfizer Victory Remains Possible | 09-24-2007
Author: Patrick Joseph Igoe, Life Sciences Patent Attorney, Independent IP Litigation Consultant

The at-risk product launch by [NasdaqGS:TEVA] Teva of generic equivalents to [NYSE:PFE] Pfizer's Neurontin® (gabapentin) might - and the emphasis is clearly on might - yet prove to be an expensive mistake by Teva. The recent Opinion by the United States Court of Appeals for the Federal Circuit...

View All GLG News by members of this Study Group

Most Common Company Types:

  • Law Firm (general practice/large)
  • Law Firm (Boutique / Specialized)

Most Common Job Types:

  • Partner
  • Director
  • Attorney

GLG's 750+ Clients Include:

40 of the leading 50
global mutual funds
15 of the leading 20
global banks
8 of the leading 10
private equity firms
90%+ client subscription renewal rate

Analytics